SCHEMBL5652630

SCHEMBL5652630

CCOc1cc(C(=O)NC2CC(C)(C)NC(C)(C)C2)ccc1-c1nc2ccc(Cl)cc2[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
HDAC6 Q9UBN7 1/20 0.44
GLA P06280 1/20 0.43
PKM P14618 1/20 0.43
EZH2 Q15910 5/20 0.42
APLNR P35414 1/20 0.42
APOBEC3A P31941 1/20 0.42
APOBEC3G Q9HC16 1/20 0.42
SIRT2 Q8IXJ6 1/20 0.42
SIRT1 Q96EB6 1/20 0.42
SIRT3 Q9NTG7 1/20 0.42
CYP2C9 P11712 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
NPC1 O15118 1/20 0.41
TP53 P04637 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5652622 0.93 MEN1 (0.49) MEN1KMT2AGLAPKMEZH2
SCHEMBL5161790 0.91 MEN1 (0.49) MEN1KMT2AGLAPKMEZH2
SCHEMBL5650740 0.89 FLT3 (0.47) MEN1KMT2AGLAPKMEZH2
SCHEMBL5653316 0.87 EZH2 (0.48) MEN1KMT2AGLAPKMEZH2
SCHEMBL5650746 0.84 ATM (0.47) MEN1KMT2AGLAPKMEZH2
SCHEMBL5648762 0.82 PDE5A (0.51) MEN1KMT2AGLAPKMEZH2
SCHEMBL5652627 0.82 HPSE (0.51) MEN1KMT2AGLAPKMEZH2
SCHEMBL5650388 0.82 MEN1 (0.45) MEN1KMT2AGLAPKMEZH2
SCHEMBL5650404 0.82 MEN1 (0.45) MEN1KMT2AGLAPKMEZH2
SCHEMBL5652641 0.82 GLA (0.48) MEN1KMT2AGLAPKMEZH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 MEN1 3545/4885KMT2A 439/4885HDAC6 537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.